Yue-peng Wang

Yue-peng Wang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2017 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
QWQian Wang
Qian Wang
YYYing Yu
Ying Yu
PZPengpai Zhang
Pengpai Zhang
YCYihe Chen
Yihe Chen
CLChangyi Li
Changyi Li
YLYigang Li
Yigang Li

1 June 2017 in Hypertension
Verified
Journal Article
Closed access
QZQing Zhou
Qing Zhou
SWSi-Si Wei
Si-Si Wei
HWHong Wang
Hong Wang
QWQian Wang
Qian Wang
WLWei Li
Wei Li
YWYue-peng Wang
Yue-peng Wang
Cardiac hypertrophy is characterized by increased myofibrillogenesis. Angiotensin II (Ang-II) is an essential mediator of the pressure overload–induced cardiac hypertrophy in part through RhoA/ROCK (small GTPase/Rho-associated coiled-coil containing protein kinase) pathway. FHOD3 (formin homology 2 domain containing 3), a cardiac-restricted member of diaphanous-related formins, is crucial in regulating myofibrillogenesis in cardiomyocytes. FHOD3 maintains inactive through autoinhibition by an intramolecular interaction between its C- and N-terminal domains. Phosphorylation of the 3 highly conserved residues (1406S, 1412S, and 1416T) within the C terminus (CT) of FHOD3 by ROCK1 is sufficient for its activation. However, it is unclear whether ROCK-mediated FHOD3 activation plays a role in the pathogenesis of Ang-II–induced cardiac hypertrophy. In this study, we detected increases in FHOD3 expression and phosphorylation in cardiomyocytes from Ang-II–induced rat cardiac hypertrophy models. Valsartan attenuated such increases. In cultured neonate rat cardiomyocytes, overexpression of phosphor-mimetic mutant FHOD3-DDD, but not wild-type FHOD3, resulted in myofibrillogenesis and cardiomyocyte hypertrophy. Expression of a phosphor-resistant mutant FHOD3-AAA completely abolished myofibrillogenesis and attenuated Ang-II–induced cardiomyocyte hypertrophy. Pretreatment of neonate rat cardiomyocytes with ROCK inhibitor Y27632 reduced Ang-II–induced FHOD3 activation and upregulation, suggesting the involvement of ROCK activities. Silencing of ROCK2, but not ROCK1, in neonate rat cardiomyocytes, significantly lessened Ang-II–induced cardiomyocyte hypertrophy. ROCK2 can directly phosphorylate FHOD3 at both 1412S and 1416T in vitro and is more potent than ROCK1. Both kinases failed to phosphorylate 1406S. Coexpression of FHOD3 with constitutively active ROCK2 induced more stress fiber formation than that with constitutively active ROCK1. Collectively, our results demonstrated the importance of ROCK2 regulated FHOD3 expression and activation in Ang-II–induced myofibrillogenesis, thus provided a novel mechanism for the pathogenesis of Ang-II–induced cardiac hypertrophy.

22 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
GLGang Li
Gang Li
LYLi Ying
Li Ying
HWHong Wang
Hong Wang
SWSi-Si Wei
Si-Si Wei
JCJie Chen
Jie Chen
YWYue-peng Wang
Yue-peng Wang
Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways

31 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJie Chen
Jie Chen
YJYe Jin
Ye Jin
HWHong Wang
Hong Wang
SWSisi Wei
Sisi Wei
DCDan Chen
Dan Chen
YWYue-peng Wang
Yue-peng Wang
The role of genetic abnormality of δ-sarcoglycan (δ-SG) gene in dilated (DCM) and hypertrophied (HCM) cardiomyopathy patients is still unfolding. In this study we first defined the promoter region and then searched for polymorphisms/mutations among the promoter, 5'-untranslated region, and the encoding exons in δ-SG gene in 104 Chinese patients with DCM, 145 with HCM, and 790 normal controls. Two novel polymorphisms were found, an 11 base-pair (bp) deletion (c.-100~-110; -) in the promoter region and a missense polymorphism of A848G resulting in p.Q283R in the highly conserved C-terminus. The prevalence of homozygous genotype -/- of c.-100~-110 was slightly higher in DCM (14.42%) and HCM patients (14.48%), as compared with normal controls (11.01%). The prevalence of genotype of 848A/G was significantly higher in DCM (6.73%; OR = 9.43; p = 0.0002), but not in HCM patients (1.38%; OR = 1.37; p = 0.62), as compared with controls (0.76%). Haplotype -_G consisting c.-100~-110 and A848G was associated with increased risk of DCM (OR = 17.27; 95%CI = 3.19–93.56; p = 0.001) but not associated with HCM (OR = 1.90; 95%CI = 0.38–9.55; p = 0.44). Co-occurrence of the genotypes -/- of c.-100~-110 and 848A/G was found in 5 patients with DCM (4.81%; OR = 39.85; p = 0.0001), none of HCM patients, and only 1 of the controls (0.13%). Both polymorphisms were also found in the Japanese population, but not in the Africans and Caucasians. C.-100~-110 resulted in a decrease of δ-SG promoter activity to 64±3% of the control level (p<0.01). Both co-immunoprecipitation and in vitro protein pull-down assays demonstrated that δ-SG-283R interacts normally to β- and γ-SG, but significantly decreased localization of β/δ/γ-SG on the plasma membrane. In conclusion, haplotype -_G composed of c.-100~-110 and A848G confers higher susceptibility to DCM in the Mongoloid population.

1 April 2017 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
YCyihe chen
yihe chen
QWQian Wang
Qian Wang
CLChang-Yi Li
Chang-Yi Li
JHJian-Wen Hou
Jian-Wen Hou
XCXiao-Meng Chen
Xiao-Meng Chen
YLYigang Li
Yigang Li

28 August 2018 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
JHJian‐Wen Hou
Jian‐Wen Hou
YFYu‐Dong Fei
Yu‐Dong Fei
WLWei Li
Wei Li
YCYi‐He Chen
Yi‐He Chen
QWQian Wang
Qian Wang
YLYigang Li
Yigang Li